Bicara Therapeutics Common Stock Operating Income

Bicara Therapeutics Common Stock's operating income stands at $-170M as of March 2026. That compares with $-110M in the prior-year period — down 63.3% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Bicara Therapeutics Common Stock reported $-170M in operating income versus $-110M a year earlier — a 63.3% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $-110M in the prior-year period — down 63.3% year over year. Sustained growth in operating income can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Bicara Therapeutics Common Stock's operating income evolved across reporting periods, while the comparison chart places BCAX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, operating income is commonly used to spot outliers. Bicara Therapeutics Common Stock's reading of $-170M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.